Medigene

Medigene EBITDA per Share

Delisted·Jul 2, 2026

The EBITDA per Share of Medigene (MDG1.DE) as of Nov 4, 2026 is -0.60 EUR. In the previous year, EBITDA per Share was 0.53 EUR — a change of -213.20% (lower).

EBITDA per Share

-0.60EUR

YoY

-213.20%

Last updated:

EBITDA per Share of Medigene is 2023 -0.60 EUR. EBITDA per Share of Medigene was 2022 0.53 EUR. It decreases by -213.20% lower compared to the previous year.

The Medigene EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2016
-0.34 EUR
Jan 1, 2017
-0.50 EUR
Jan 1, 2018
-0.66 EUR
Jan 1, 2019
-0.74 EUR
Jan 1, 2020
-0.74 EUR
Jan 1, 2021
-0.26 EUR
Jan 1, 2022
0.53 EUR
Jan 1, 2023
-0.60 EUR
The Medigene EBITDA per Share history
YEAREBITDA per ShareYoY
-0.60EUR-213.20%
0.53EUR-303.57%
-0.26EUR-65.05%
-0.74EUR+0.17%
-0.74EUR+11.37%
-0.66EUR+33.66%
-0.50EUR+47.61%
-0.34EUR-13.05%
-0.39EUR+127.97%
-0.17EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medigene Stock analysis

What does Medigene do? Medigene AG, based in Planegg, Germany, is a biotechnology company specializing in developing innovative cancer treatment platforms. The company focuses on personalized T cell-based immunotherapies, including TCR-modified T cells for adoptive therapy, dendritic cell vaccines for low tumor burdens, and T-cell-specific monoclonal antibodies. It operates offices in Martinsried, Germany, and in Washington DC and San Diego, USA, with 136 employees. Medigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medigene stock

EBITDA per Share of Medigene is -0.60 EUR in 2023.

EBITDA per Share of Medigene changed from 0.53 EUR to -0.60 EUR, representing a -213.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Medigene since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Medigene

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Medigene